Jacobs Equity LLC Makes New Investment in CRISPR Therapeutics AG $CRSP

Jacobs Equity LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,090 shares of the company’s stock, valued at approximately $634,000.

A number of other large investors have also recently made changes to their positions in the stock. ARK Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after purchasing an additional 735,084 shares during the last quarter. Orbis Allan Gray Ltd increased its stake in CRISPR Therapeutics by 19.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company’s stock worth $312,026,000 after buying an additional 968,060 shares during the period. Capital International Investors lifted its holdings in CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after buying an additional 243,487 shares in the last quarter. State Street Corp lifted its holdings in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after buying an additional 859,334 shares in the last quarter. Finally, GSK plc purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $168,890,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of research analyst reports. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a research note on Thursday, June 11th. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. Truist Financial raised CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $67.78.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $54.09 on Friday. The firm’s fifty day simple moving average is $52.68 and its two-hundred day simple moving average is $53.09. The firm has a market capitalization of $5.22 billion, a P/E ratio of -8.70 and a beta of 1.74. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a 12-month low of $43.23 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The business had revenue of $1.46 million for the quarter. Analysts forecast that CRISPR Therapeutics AG will post -4.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the transaction, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at $11,952,336.78. This represents a 3.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 3,182 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel owned 94,308 shares of the company’s stock, valued at approximately $4,411,728.24. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,988 shares of company stock worth $828,167 in the last ninety days. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.